Date: 2026-03-24Category: Press ReleaseState: Union GovernmentCountry: India
On the occasion of "World Tuberculosis Day", India launches first-of-its-kind global clinical study integrating traditional Ayurveda with modern TB care regimens; another step closer to "TB Mukt Bharat", says Dr Jitendra Singh
**Executive Summary**
On March 24, 2026, the Government of India launched a first-of-its-kind global clinical study integrating traditional Ayurveda with modern Anti-Tuberculosis Treatment (ATT) to support the "TB Mukt Bharat" initiative. The study, a collaboration between the Department of Biotechnology (DBT) and the Ministry of Ayush, aims to scientifically validate Ayurveda as a supportive therapy to improve nutritional outcomes and patient recovery. Key targets include the enrollment of 1,250 patients across eight national institutions to address India’s tuberculosis burden.
**Key Points / Main Content**
**Clinical Study Objectives and Methodology**
* Evaluates Ayurveda as an adjunct to standard ATT to improve body weight, quality of life, and nutritional outcomes.
* Enrolls 1,250 newly diagnosed TB patients across eight premier institutions nationwide.
* Utilizes advanced scientific tools, including MRI, DEXA scans, immune profiling, and single-cell RNA sequencing, to examine TB-associated cachexia.
* Focuses on the safety, tolerability, and long-term recovery of patients beyond a simple microbiological cure.
**National TB Progress and Strategy**
* Reports a 21% reduction in TB incidence since 2015, with 2024 figures showing approximately 187 cases per 100,000 population.
* Adopts a "whole-of-government" and "whole-of-science" approach, integrating modern biotechnology with traditional knowledge systems.
* Emphasizes patient-centric care, universal drug susceptibility testing, and digital adherence technologies under the National TB Elimination Programme.
**Existing Research and Genomic Surveillance**
* **RePORT India:** A large-scale research consortium that has enrolled over 4,500 TB patients to inform global policy guidelines.
* **InTGS Consortium:** An initiative sequencing more than 32,000 *Mycobacterium tuberculosis* clinical strains to assist in drug discovery and diagnostics.
* **Data Driven Research:** Ongoing efforts in vaccine development, host-pathogen biology, and containment of drug-resistant TB.
**Impact Analysis**
**TB Patients**
**Impact**
Patients gain access to a holistic treatment model that addresses post-treatment complications such as weakness, weight loss, and pulmonary impairment.
**Action Required**
Enrolled participants must adhere to the integrated treatment protocols and participate in the required clinical assessments and monitoring.
**Department of Biotechnology (DBT) and Ministry of Ayush**
**Impact**
These bodies are responsible for the convergence of traditional medicine and modern science, establishing a global precedent for integrative healthcare.
**Action Required**
Collaborate on study implementation, ensure rigorous scientific validation of protocols, and manage the national repository of clinical strains.
**Research Institutions and Scientists**
**Impact**
Institutions receive the opportunity to use advanced biotechnological tools to study immune-metabolic conditions and host-directed therapies.
**Action Required**
Conduct clinical trials across the eight designated centers and generate evidence-based data on the efficacy of Ayurveda as a supportive therapy.
**Communities and Civil Society**
**Impact**
A shift toward a "whole-of-society" approach aims to reduce the social stigma that often delays TB diagnosis and treatment.
**Action Required**
Engage in awareness campaigns to encourage early diagnosis and provide community-level lifestyle and nutritional support for recovering patients.
Key Entities Referenced
National TB Elimination Programme: The national health program under which India provides universal drug susceptibility testing and patient-centric care to eradicate tuberculosis.
Department of Biotechnology (DBT): The scientific department leading the clinical study to evaluate Ayurveda as an adjunct to standard anti-tuberculosis treatment.
Ministry of Ayush: The collaborating ministry responsible for integrating traditional medicine systems with modern scientific validation in TB care.
TB Mukt Bharat: The national initiative and campaign targeted at making India tuberculosis-free through innovative and collaborative efforts.
RePORT India: One of the largest TB research consortia that generates evidence for global policy frameworks and nutritional guidelines.
Ministry of Science & Technology
On the occasion of "World Tuberculosis Day",
India launches first-of-its-kind global clinical
study integrating traditional Ayurveda with
modern TB care regimens; another step closer to
"TB Mukt Bharat", says Dr Jitendra Singh
Modern science and traditional knowledge come together for
holistic management with better outcomes in Tuberculosis:
Dr Jitendra Singh
Patient-centric, integrated approach key to TB elimination;
India seeing steady decline in TB incidence through
innovation: Dr Jitendra Singh
Whole-of-science, whole-of-government approach to drive
scientific validation of Ayurveda and transform TB treatment
outcomes: Dr Jitendra Singh
Ayurveda shows strong potential as supportive therapy in TB
care; study reflects India’s whole-of-nation commitment to TB
elimination: Dr Jitendra Singh
Posted On: 24 MAR 2026 5:30PM by PIB Delhi
NEW DELHI, March 24: India today announced world's first-ever, landmark clinical study that will, for
the first time globally, scientifically evaluate Ayurveda as an adjunct to standard Anti-Tuberculosis
Treatment (ATT), with Union Minister of State (Independent Charge) for Science & Technology, Earth
Sciences; Minister of State in the PMO, Personnel, Public Grievances and Pensions, Department of
Atomic Energy and Department of Space, Dr. Jitendra Singh, describing it as a unique convergence of
modern biotechnology and traditional knowledge systems to address tuberculosis in a holistic and patient-
centric manner.
Speaking on the occasion of World Tuberculosis Day, Dr. Jitendra Singh said India, which accounts for
nearly 25% of the global TB burden, has registered a significant decline in incidence to about 187 cases
per 100,000 population in 2024, reflecting a 21% reduction since 2015. Quoting Prime Minister Shri
Narendra Modi, he said, “The decline in TB incidence is an outcome of India’s dedicated and innovative
efforts. Through a collective spirit, we will keep working towards a TB-free India,” adding that this
reflects the country’s steady movement in the right direction.Dr. Jitendra Singh said India has adopted an ambitious and accelerated pathway towards TB elimination,
strengthening early diagnosis, universal drug susceptibility testing, digital adherence technologies, and
patient-centric care under the National TB Elimination Programme.
Recalling the historical journey of tuberculosis, the Minister said there was a time when TB had no
effective treatment and patients were isolated in sanatoriums, often facing fear and social stigma. He said
tuberculosis had deeply entered social narratives, literature, and films, largely because of the absence of
treatment in earlier decades. With the advent of anti-tubercular drugs and evolving medical science, the
disease gradually became treatable, marking a major transition in public health.
The Minister said that despite this progress, tuberculosis continues to present complex challenges. Patients
often suffer from treatment-related toxicity, undernutrition, immune suppression, and long-term
pulmonary impairment even after microbiological cure. He added that the growing burden of drug-
resistant TB further complicates the situation and calls for innovative and multidisciplinary solutions.
Dr. Jitendra Singh said tuberculosis cannot be seen in isolation, as communicable and non-communicable
diseases increasingly coexist and interact. He pointed out the reciprocal relationship between TB and
conditions such as diabetes, where each can aggravate the other, making integrated approaches essential
for effective disease management.
Highlighting the role of the Department of Biotechnology, the Minister said DBT has been driving a wide
range of initiatives in TB research, including host-pathogen biology, drug discovery, vaccine development,
and genomic surveillance. He referred to the RePORT India programme, one of the largest TB research
consortia, which has enrolled over 4,500 TB patients and more than 5,000 household contacts, generating
evidence that has contributed to global policy frameworks, including WHO guidelines on nutrition and
tuberculosis.
The Minister also referred to the Data Driven Research to Eradicate TB programme, under which several
initiatives have been undertaken, including the Indian Tuberculosis Genomic Surveillance (InTGS)
Consortium. He said more than 32,000 Mycobacterium tuberculosis clinical strains are being sequenced
under this initiative, creating a valuable national repository to support drug discovery, diagnostics, and
containment of drug-resistant TB.
Dr. Jitendra Singh said that even after successful treatment, many TB patients continue to experience
weakness, weight loss, and compromised quality of life, underlining the need for supportive and host-
directed therapies. The Minister said India’s rich heritage of Ayurveda offers unique opportunities for such
interventions, particularly in improving nutrition, immunity and overall recovery.
Announcing the collaborative clinical study between the Department of Biotechnology and the Ministry of
Ayush, he said this initiative is the first-of-its-kind not only in India but also globally, as it seeks to
validate traditional medicine through rigorous scientific evaluation. He said the study reflects the spirit of
“whole-of-science,” by integrating biotechnology and Ayurveda; “whole-of-government,” through
collaboration between ministries; and “whole-of-nation,” with participation of over 1,200 patients across
premier institutions nationwide.
Dr. Jitendra Singh said tuberculosis is too serious a challenge to be addressed by the government alone
and cannot be left only to the healthcare system or families. He called for a collective societal effort
involving communities, civil society organisations and awareness campaigns to remove stigma associated
with TB, noting that patients often tend to hide symptoms due to social perceptions, which delays
diagnosis and treatment.The Minister emphasised that alongside medical treatment, attention must also be
given to nutritional recovery, lifestyle support and community-level engagement, as these factors play a
crucial role in ensuring complete and sustained recovery.The event marked the launch of the collaborative programme between the Department of Biotechnology,
Ministry of Science & Technology, and the Ministry of Ayush. It was attended by Union Minister of State
(Independent Charge) for Ministry of Ayush, Shri Prataprao Jadhav; Secretary, Department of
Biotechnology, Dr. Rajesh S. Gokhale; Secretary, Ministry of Ayush, Vaidya Rajesh Kotecha; Director
General, Central Council for Research in Ayurvedic Sciences (CCRAS), Prof. Vaidya Rabinarayan
Acharya; Director, BRIC-National Institute of Immunology (NII), Dr. Debasisa Mohanty; along with
senior scientists, researchers and representatives from leading institutions across the country.
Providing an overview of the study, DG, CCRAS, Prof. Vaidya Rabinarayan Acharya said the initiative
has been developed under the MoU signed between the Ministry of Ayush and the Department of
Biotechnology on 25 May 2022 and has progressed through consultations, protocol finalisation, and
approvals. The study will enrol 1,250 newly diagnosed TB patients across eight institutions and evaluate
Ayurveda as an adjunct to standard treatment, focusing on body weight, nutritional outcomes, disease
progression, quality of life, safety, and tolerability.
Director, BRIC-NII, Dr. Debasisa Mohanty said the study will also examine tuberculosis-associated
cachexia as an immune-metabolic condition, using advanced tools such as DEXA, MRI, immune
profiling, metabolomics, and single-cell RNA sequencing to understand changes in body composition,
immune function, and energy metabolism, and to assess how integrative interventions influence recovery
and long-term outcomes.
Union Minister of State (Independent Charge) for Ministry of Ayush, Shri Prataprao Jadhav said the
initiative reflects a broader vision of healthcare where the focus extends beyond curing infection to
ensuring complete recovery, improved nutrition, and enhanced quality of life through integration of
Ayurveda with modern medicine.
DBT Secretary, Dr. Rajesh S. Gokhale said the programme builds on the Department of Biotechnology’s
extensive work in TB research, including diagnostics, vaccine development, and cohort studies, and
represents an important step towards generating evidence for integrative and patient-centric healthcare
approaches.
Concluding, Dr. Jitendra Singh said the fight against tuberculosis requires innovation, integration, and
collective responsibility at every level, adding that such initiatives will accelerate India’s journey towards
a TB-free nation while setting a global example in combining traditional wisdom with modern science.
PHOTO: Union Minister Dr Jitendra Singh addressing the an event on the occasion of “World
Tuberculosis Day” programme at Vigyan Bhawan, New Delhi on Tuesday.*****
NKR/AK/MJ/NM
(Release ID: 2244584) Visitor Counter : 164
Read this release in: ही